Guardant blood test detects 83% of colorectal cancer cases, but fewer in early stage
Analysts said the test is likely to meet the bar for FDA approval, but its flaws in detecting early-stage cancer weaken its chances against Exact Sciences’ stool-based test, Cologuard.
Guardant blood test detects 83% of colorectal cancer cases, but fewer in early stage Read More »
